SCHEMBL6488966

SCHEMBL6488966

CCOc1ccc(Cn2c(C)nc3c(C)cc(-c4cccc(C(=O)O)c4)cc32)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
EIF4EBP1 Q13541 1/20 0.39
MRGPRX4 Q96LA9 2/20 0.39
ALOX5AP P20292 2/20 0.39
PPARG P37231 3/20 0.39
PIK3C2B O00750 2/20 0.38
NR4A1 P22736 1/20 0.38
NR4A2 P43354 1/20 0.38
NR4A3 Q92570 1/20 0.38
DCTPP1 Q9H773 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
TP53 P04637 1/20 0.38
PKM P14618 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
MITF O75030 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6497678 0.93 PTPN11 (0.46) EIF4EBP1PPARGNR1H4
SCHEMBL6498192 0.92 RXRA (0.43) RXRARXRBMRGPRX4ALOX5APPPARG
SCHEMBL6488456 0.90 DCTPP1 (0.44) RXRARXRBPPARGNR4A2DCTPP1
SCHEMBL6501593 0.89 KDM4C (0.44) DCTPP1
SCHEMBL6498778 0.89 AGTR1 (0.42) RXRARXRBMRGPRX4PPARG
SCHEMBL6489299 0.88 PPARG (0.45) RXRARXRBEIF4EBP1ALOX5APPPARG
SCHEMBL6496733 0.87 ALOX5AP (0.47) RXRARXRBMRGPRX4ALOX5APPPARG
SCHEMBL6490645 0.87 PTGDR (0.44) RXRARXRBEIF4EBP1MRGPRX4ALOX5AP
SCHEMBL6488960 0.87 PTPN11 (0.44) NR1H4
SCHEMBL6489346 0.86 MRGPRX4 (0.46) MRGPRX4PPARGNR4A1NR4A2NR4A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD RXRA 2329/4885RXRB 2252/4885EIF4EBP1 1623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.